|
CELG's Capital Expenditures Growth by Quarter and Year
Celgene's Capital Expenditures results by quarter and year
Select the Comparisons :
|
|
Select the Ratio:
|
Capital Expenditures Growth Y/Y▼
|
Capital Expenditures Growth Y/Y▼
|
CELG Capital Expenditures (in millions $) |
FY 2019 |
FY 2018 |
FY 2017 |
FY 2016 |
IV Quarter |
December |
-
|
98.00
|
103.00
|
66.40
|
III Quarter |
September |
468.00
|
64.00
|
44.00
|
66.50
|
II Quarter |
June |
60.00
|
80.00
|
70.00
|
43.70
|
I Quarter |
March |
69.00
|
88.00
|
62.00
|
59.60
|
FY |
|
597.00
|
330.00
|
279.00
|
236.20
|
CELG Capital Expenditures third quarter 2019 Y/Y Growth Comment |
Celgene Corp showed record Capital Expenditures surge in the third quarter 2019 with 631.25% from the third quarter 2019 2018, to $ 468.00 millions.
Looking into third quarter 2019 results within Major Pharmaceutical Preparations industry 19 other companies have achieved higher Capital Expenditures growth. While Celgene Corp' s Capital Expenditures doubling of 631.25% ranks overall at the positon no. 153 in the third quarter 2019.
|
CELG Capital Expenditures ( Y/Y Growth %) |
2019
|
2018 |
2017 |
2016 |
IV Quarter |
December |
- |
-4.85 % |
55.12 % |
-52.84 % |
III Quarter |
September |
631.25 % |
45.45 % |
-33.83 % |
31.68 % |
II Quarter |
June |
-25 % |
14.29 % |
60.18 % |
-17.08 % |
I Quarter |
March |
-21.59 % |
41.94 % |
4.03 % |
40.9 % |
FY |
|
- |
18.28 % |
18.12 % |
-17.5 % |
CELG Capital Expenditures (Quarter on Quarter Growth %) |
2019
|
2018 |
2017 |
2016 |
IV Quarter |
December |
- |
53.13 % |
134.09 % |
-0.15 % |
III Quarter |
September |
680 % |
-20 % |
-37.14 % |
52.17 % |
II Quarter |
June |
-13.04 % |
-9.09 % |
12.9 % |
-26.68 % |
I Quarter |
March |
-29.59 % |
-14.56 % |
-6.63 % |
-57.67 % |
FY (Year on Year) |
|
- |
18.28 % |
18.12 % |
-17.5 % |
Capital Expenditures Y/Y Growth Statistics |
High |
Average |
Low |
631.25 % |
34.21 % |
-100 % |
(Sep 30 2019) |
|
(Dec 31 2011) |
|
Capital Expenditures Y/Y Growth Statistics |
High |
Average |
Low |
631.25 % |
34.21 % |
-100 % |
(Sep 30 2019) |
|
(Dec 31 2011) |
|
Capital Expenditures by Quarter for the Fiscal Years 2016, 2017, 2018, 2019 |
Celgene's Q/Q Capital Expenditures Growth
Capital Expenditures Q/Q Growth Statistics |
High |
Average |
Low |
952.24 % |
47.62 % |
-100 % |
(Dec 31 2015) |
|
|
CELG's III. Quarter Q/Q Capital Expenditures Comment |
Celgene Corp achieved in the III. Quarter 2019 above company average sequential Capital Expenditures doubling of 680%, to $ 468.00 millions, from $60.00 millions in the second quarter. CELG is impressively improving, not only claiming better then regular gain, but also improving speed, Sophie Lambert, Major Pharmaceutical Preparations industry advisor allocated in Amsterdam added.
Within Major Pharmaceutical Preparations industry 8 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Celgene's Capital Expenditures growth quarter on quarter, overall rank is 85. |
|
|
Capital Expenditures Q/Q Growth Statistics |
High |
Average |
Low |
952.24 % |
47.62 % |
-100 % |
(Dec 31 2015) |
|
|
CELG's III. Quarter Q/Q Capital Expenditures Comment |
Celgene Corp achieved in the III. Quarter 2019 above company average sequential Capital Expenditures doubling of 680%, to $ 468.00 millions, from $60.00 millions in the second quarter. CELG is undergoing a remarkable growth, with claiming higher then average increase, and also accelerating rate, Sophie Lambert, Major Pharmaceutical Preparations industry advisor allocated in Amsterdam said.
Within Major Pharmaceutical Preparations industry 8 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Celgene's Capital Expenditures growth quarter on quarter, overall rank is 85. |
|
Celgene's 12 Months Capital Expenditures Growth Year on Year
Capital Expenditures TTM Growth |
12 Months Ending (Sep 30 2019) |
12 Months Ending (Jun 30 2019) |
12 Months Ending (Mar 31 2019) |
12 Months Ending (Dec 31 2018) |
12 Months Ending (Sep 30 2018) |
Cumulative Capital Expenditures 12 Months Ending |
$ 695.00 |
$ 291.00 |
$ 311.00 |
$ 330.00 |
$ 335.00 |
Y / Y Capital Expenditures Growth (TTM) |
107.46 % |
-7.62 % |
1.97 % |
18.28 % |
38.2 % |
Year on Year Capital Expenditures Growth Overall
Ranking |
# 918 |
# 754 |
# 768 |
# 1392 |
# 900 |
Seqeuential Capital Expenditures Change (TTM) |
138.83 % |
-6.43 % |
-5.76 % |
-1.49 % |
6.35 % |
Seq. Capital Expenditures Growth (TTM) Overall
Ranking |
# 1579 |
# 1981 |
# 974 |
# 2014 |
# 1297 |
Cumulative Capital Expenditures growth
Comment |
Although Celgene's Annual Capital Expenditures growth year on year were below company's average 141.59% , Capital Expenditures announced in the Sep 30 2019 period, show improvement in Capital Expenditures trend, to cumulative trailing twelve month growth of 107.46% year on year, from -7.62% in Jun 30 2019.
In the Healthcare sector 151 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 754 to 918. |
Capital Expenditures TTM Q/Q Growth Statistics |
High |
Average |
Low |
3419.24 % |
141.59 % |
-21.96 % |
|
|
|
|
|
Capital Expenditures TTM Y/Y Growth Statistics |
High |
Average |
Low |
3419.24 % |
141.59 % |
-21.96 % |
|
|
|
Capital Expenditures TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 80 |
Sector |
# 230 |
S&P 500 |
# 1579 |
|
Cumulative Capital Expenditures growth
Comment |
Although Celgene's Annual Capital Expenditures growth year on year were below company's average 141.59% , Capital Expenditures announced in the Sep 30 2019 period, show improvement in Capital Expenditures trend, to cumulative trailing twelve month growth of 107.46% year on year, from -7.62% in Jun 30 2019.
In the Healthcare sector 151 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 754 to 918. |
Capital Expenditures TTM Q/Q Growth Statistics |
High |
Average |
Low |
3419.24 % |
141.59 % |
-21.96 % |
|
|
|
Capital Expenditures TTM Y/Y Growth Statistics |
High |
Average |
Low |
3419.24 % |
141.59 % |
-21.96 % |
|
|
|
Capital Expenditures TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 80 |
Sector |
# 230 |
S&P 500 |
# 1579 |
Companies with similar Capital Expenditures doubling for the quarter ending Sep 30 2019 within Healthcare Sector | Y/Y Change % | Capital Expenditures for the quarter ending Sep 30 2019 | Chembio Diagnostics Inc | 1,063.37% | $ 1,063.367 millions | X4 Pharmaceuticals Inc | 1,057.14% | $ 1,057.143 millions | Veru Inc | 1,034.85% | $ 1,034.855 millions | Corbus Pharmaceuticals Holdings Inc | 1,028.74% | $ 1,028.738 millions | Arrowhead Pharmaceuticals Inc | 1,003.77% | $ 1,003.769 millions | Janone Inc | 945.00% | $ 945.000 millions | Allogene Therapeutics inc | 861.84% | $ 861.840 millions | Xtant Medical Holdings Inc | 860.00% | $ 860.000 millions | Lifevantage Corp | 774.42% | $ 774.419 millions | Pacific Biosciences Of California Inc | 763.54% | $ 763.542 millions | Genocea Biosciences Inc | 758.97% | $ 758.974 millions | Adma Biologics Inc | 756.52% | $ 756.518 millions | Charles River Laboratories International inc | 746.82% | $ 746.819 millions | Tearlab Corp | 740.00% | $ 740.000 millions | Bionik Laboratories Corp | 734.01% | $ 734.006 millions | Akebia Therapeutics Inc | 723.78% | $ 723.779 millions | Vivani Medical Inc | 721.43% | $ 721.429 millions | Regulus Therapeutics Inc | 704.55% | $ 704.545 millions | Glucotrack Inc | 693.53% | $ 693.534 millions | Insmed Inc | 688.33% | $ 688.331 millions | Esperion Therapeutics inc | 678.26% | $ 678.261 millions | Talphera Inc | 673.12% | $ 673.118 millions | Dynavax Technologies Corporation | 666.22% | $ 666.222 millions | Pulse Biosciences Inc | 640.28% | $ 640.278 millions | Celgene Corp | 631.25% | $ 631.250 millions | Lightwave Logic Inc | 629.84% | $ 629.835 millions | Lifeloc Technologies Inc | 628.49% | $ 628.486 millions | Standard Biotools Inc | 579.80% | $ 579.798 millions | Quotient Limited | 572.99% | $ 572.986 millions | Corcept Therapeutics Inc | 535.56% | $ 535.556 millions |
|